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Background: Angiogenesis is a general hallmark of cancer; therefore, the inhibition of tumor-derived angiogenesis
is considered to be an attractive target in the development of anti-cancer agents. Sa-mi-yeon-geon-tang (SMYGT),
a decoction that consists of four natural medicinal products, has been traditionally prescribed in Oriental medicine
to treat diverse diseases, including cancer. In the present study, we investigated the anti-angiogenic potential of
SMYGT in vitro and in ovo.
Methods: The anti-angiogenic potential of SMYGT was evaluated using conventional in vitro assays with human
umbilical vein endothelial cells (HUVECs) and chorioallantoic membrane (CAM) assays with fertilized eggs. The
expression changes of pro-angiogenic proteins and intracellular signaling in HUVECs following SMYGT treatment
were determined by quantitative polymerase chain reaction, gelatinase zymography, and western blot analysis.
Results: SMYGT efficiently inhibited three-dimensional capillary-like tube formation by HUVECs on extracellular
matrix supports, as well as new vessel formation on CAMs. SMYGT inhibited cell adhesion to the extracellular
matrix and HUVEC cell invasion through Matrigel without affecting cell proliferation, viability, and motility.
These anti-angiogenic effects of SMYGT in HUVECs were related to decreases in the phosphorylation of focal
adhesion kinase and the expression of matrix metallopeptidase-2 activity.
Conclusions: SMYGT exhibited an anti-angiogenic potential in both in vitro and in ovo experiments, which may
partially contribute to its anti-tumor effect in clinical conditions. We suggest that SMYGT may be a promising
source material for the development of anti-cancer chemotherapeutics that target angiogenesis.
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Because cancer is a complex, multi-factorial disease,
treating cancer based on a single-target/single-compo-
nent strategy may be less effective than using a multi-
target/multi-component strategy. In fact, oncology de-
partment currently administer various combination of
chemical and/or recombinant drugs to cancer patients,
and many ongoing clinical studies are investigating the
efficacy of cocktail therapies in different types of cancer
[1-4]. Medicinal herbs or the prescription drugs derived
from them, which have been traditionally used for* Correspondence: nosookim@kiom.re.kr
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unless otherwise stated.disease management, can be promising source materials
in the development of anticancer drugs because they are
originally based on multi-target/multi-component strat-
egies. Additionally, medicinal herb extracts can be pre-
scribed as adjuvants to produce synergistic effects with
conventional anticancer drugs or to relieve the adverse
side effects of the anticancer drugs. The rationale of
using a combination of medicinal plants was demon-
strated by Cheng’s research group, who showed that the
four-herb Chinese medicine PHY906 reduced CPT-11
(irinotecan)-induced intestinal toxicity and increased the
anticancer activity of CPT-11 through multiple mecha-
nisms that act simultaneously [5]. Natural products,
particularly botanical drugs, have been shown to beis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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or in combination with chemotherapeutics [6-8].
In traditional Oriental medicine, cancer is referred to
as an accumulation of mass in the body. Therefore, nat-
ural products that aim to soften and resolve the hard
mass or lumps have long been used to treat cancer. Sa-
mi-yeon-geon-tang (SMYGT) is a decoction composed
of the combination of four natural products with medi-
cinal values, including Sargassum, Laminariae Thallus,
Prunellae Spica, and Ostreae Concha (Table 1) in an
equal weight ratio. SMYGT and its component drugs
have been used to soften and dissipate the abnormal
hard mass [9]. The name of the formula translates as fol-
lows: Sa (four)-mi (taste)-yeon (soften)-geon (hardness)-
tang (decoction). In 1983, a Chinese research group re-
ported that SMYGT showed anti-tumor effects when
administered to 511 cancer patients, including liver,
stomach, and colorectal cancer [10]. Bae et al. demon-
strated that modified SMYGT which included three
additional herbs, showed anti-cancer or anti-metastatic
effects by inhibiting DNA topoisomerase I activity and
angiogenic events [9]. When administered to experimen-
tal mice with 1,2-dimethylhydrazine-induced murine
colorectal cancer, modified SMYGT that included four
additional herbs demonstrated anti-carcinogenic activity.
However, the anticancer mechanism of SMYGT itself is
unknown. In our preliminary in vitro activity screening,
SMYGT was identified as a hit that showed anti-
angiogenic potential. In this study, we demonstrate that
SMYGT has anti-angiogenic potential in vitro and in
ovo, and we suggest a feasible underlying mechanism.
Methods
Preparation of SMYGT extracts
The four components of SMYGT were purchased from
Kwangmyungdang Medicinal Herbs (Ulsan, Republic of
Korea). Their identities were confirmed by Dr. Go Ya
Choi, Herbal Medicines Resources Group, Korea Insti-
tute of Oriental Medicine (KIOM). The voucher speci-
mens of Sargassum (KIOM010011), Laminariae Thallus
(KIOM010019), Prunellae Spica (KIOM010023), and
Ostreae Concha (KIOM010022) were deposited at
KM-Based Herbal Drug Development Group, KIOM.
The crude water extract was prepared by boiling a
300 g of finely pulverized dried materials that consist
of equal ratio of each component (75 g of eachTable 1 Four components of SMYGT
Herbal name Latin name Genus Weight Ratio
Sargassum Sargassum fusiforme Sargassaceae 1
Laminariae Thallus Laminaria japonica Laminariaceae 1
Prunellae Spica Prunella vulgaris Labiatae 1
Ostreae Concha Ostrea gigas Ostreidae 1component) in 8 L of distilled water for 4 h. The ex-
tract was filtered through Whatman No.2 filter paper,
concentrated in a rotary evaporator (EYELA, Tokyo,
Japan), and lyophilized in a freeze dryer (Ilshin Bio
Base, Dongducheon, Republic of Korea) The yield of
the extraction (78.5 g) was approximately 26.2% (w/w).
The extract was dissolved in phosphate-buffered saline
(PBS) at a concentration of 80 mg/mL and stored
at −70°C until use.
Cell culture
Human umbilical vein endothelial cells (HUVECs) were
purchased from Lonza (Walkersville, MD, USA), and
cultured with an EGM-2 endothelial cell growth media
kit (Lonza) in a humidified atmosphere with 5% CO2 at
37°C. The culture medium was replaced every other day.
All in vitro experiments were performed using HUVECs
at a passage number less than 10.
Cell proliferation and viability
One day before drug treatment, 50,000 cells per well
were inoculated into a 24-well tissue culture plate con-
taining 475 μL of EGM-2. Cells were treated with 25 μL
of serially diluted test drugs and were maintained for
various periods. Sulforaphane (5 μM) and vehicle (PBS)
were administered in parallel as positive and negative
control drugs, respectively. To determine cell prolifera-
tion and viability, the cultured medium was saved, and
the cells were washed with PBS and trypsinized. The
cells were resuspended in the saved cultured medium.
The numbers of total (viable and dead) and dead cells
were determined using an ADAM-MC automatic cell
counter (NanoEnTek, Seoul, Republic of Korea) as
described by Yi et al. [11]. In brief, the number of total
(viable and dead) cells was determined using the AccuStain
T solution, a cell lysis solution supplemented with a cell
membrane-impermeable fluorescent dye (propidium iodide,
PI). The number of dead cells was determined using the
AccuStain N solution, a normal saline solution containing
PI. The 1:1 mixtures of cell suspension with AccuStain T or
with AccuStain N were loaded into the T and N channels
of AccuChip, respectively. The number of total cells and
the cell viability were automatically calculated by the fol-
lowing equation: cell viability (%) = [No. of AccuStain T
positive total cells – No. of AccuStain N positive dead
cells]/[No. of AccuStain T positive total cells] × 100.
In vitro tube formation assay
The effect of SMYGT on HUVEC tube formation was
evaluated using the Cultrex In Vitro Angiogenesis Assay
Kit (Trevigen, Gaithersburg, MD, USA), according to
the manufacturer’s instructions. Briefly, HUVECs were
resuspended in EGM-2 containing SMYGT (100 ~
400 μg/mL) or vehicle (PBS) and then seeded at 1.5 ×
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membrane extracts (BME). Sulforaphane (5 μM) was ad-
ministered in parallel as a positive control drug. After a
12 h incubation period, images of the capillary-like tube
networks were obtained using an inverted microscope.
The quantification of tube length and branch points was
performed with MetaMorph image analysis software
(Molecular Devices, Downingtown, PA, USA).
Chick chorioallantoic membrane (CAM) assay
The anti-angiogenic potential of SMYGT was evaluated
with an in ovo CAM assay. Fertilized eggs purchased
from CJ (Seoul, Republic of Korea) were incubated at
37°C in an egg incubator (R-COM, Gimhae, Republic of
Korea), with 70% relative humidity. This time point was
designated as embryonic day (ED) 0. At ED 3, approxi-
mately 2 ~ 3 mL of albumin was removed, and an egg-
shell window was constructed. At ED 4.5, the test drugs
dissolved in 80% ethanol were loaded on a one-quarter
sized Thermanox coverslip (Nunc, Naperville, IL, USA)
and the solvent was completely evaporated in a clean
bench. The dried Thermanox coverslip containing drugs
were then applied to the CAM. Solvent only and 1 μg/
egg of retinoic acid (RA, Sigma-Aldrich, St. Louis, MO,
USA) was loaded in parallel as a negative and a positive
control, respectively. At ED 6.5, the inhibition zone of
angiogenesis was visualized by injecting 10% skimmed
milk into the CAM. The drug response was scored as
positive when CAM showed an avascular zone that was
similar to the RA-treated CAM.
Wound healing assay
HUVECs were cultured in 24-well plates to > 90% con-
fluence. Using a 200 μL pipet tip, a straight scratch was
made through the cell sheet. The cells were photo-
graphed (t = 0 h), rinsed with fresh growth medium and
then further incubated in fresh growth medium contain-
ing SMYGT or a vehicle (PBS). Sulforaphane (5 μM) was
administered in parallel as a positive control drug. After
12 h of incubation, digital images were recorded using
an inverted microscope, and quantification of the healed
area (%) was determined using the MetaMorph image
analysis software according to the following formula:
healed area (%) = [1-wounded area (t = 12 h)/wounded
area (t = 0 h)] × 100.
Cell adhesion assay
HUVECs (2 × 104) were inoculated into 24-well plates
pre-coated with Matrigel (BD, NJ, USA) in a growth
medium containing SMYGT or a vehicle (PBS). Sulfo-
raphane (5 μM) was administered in parallel as a positive
control drug. After 2 h, wells were washed with PBS to
remove unattached cells. The adherent cells were fixed
with 70% ethanol for 10 min and visualized with acommercially available cell staining solution (Trevigen).
The cells were washed with water and completely dried
by turning the plates upside down. Stained cells in three
randomly selected fields per well (× 100 magnification)
were digitally captured and counted using an inverted
microscope.
Cell invasion assay
The invasion assays were performed in 24-well plates
equipped with cell culture inserts with a transparent
PET membrane containing 8 μm pores (BD). One day
before the assay, HUVECs were serum-starved in EBM
basal medium (Lonza) supplemented with 0.5% FBS.
The cells were harvested and resuspended at a concen-
tration of 5 × 105/mL in serum-free medium. Two
hundred microliters (1×105 cells) of resuspended cell
solution with SMYGT or vehicle (PBS) were added to
the inserts pre-coated with diluted Matrigel. EGM-2
complete medium was added to the bottom chamber as
a chemo-attractant. Sulforaphane (5 μM) was adminis-
tered in parallel as a positive control drug. After 16 h,
the media were carefully aspirated from the inserts and
the membrane filters were fixed with 70% ethanol for
10 min. The cells on the upper surface of the filters were
completely removed using cotton swabs, and the invad-
ing cells on the opposite surface of the filter were
stained with methylene blue. The GAPDH-visualized in-
vading cells in three randomly selected fields per well (×
100 magnification) were digitally captured and counted
using an inverted microscope.
Activity gel of matrix metallopeptidase-2 (MMP2)
The activity of MMP2 secreted by HUVECs into the
culture media was determined using an MMP activity
gel. The culture media containing 40 μg of protein
were loaded onto a 7.5% sodium dodecyl sulphate -
polyacrylamide gel electrophoresis (SDS-PAGE) gel that
had been copolymerized with 1 mg/mL of gelatin
(Sigma-Aldrich). After washing the gels 4 times to re-
move SDS, the enzyme activity was initiated by incubat-
ing the gel in a substrate buffer containing 50 mM Tris
(pH 7.6), 1 μM ZnCl2, and 5 mM CaCl2 overnight at
37°C. The degradation of the gelatin substrate by MMP2
was visualized by staining the gel with a 0.1% Coomassie
blue solution.
Quantitative polymerase-chain-reaction (qPCR)
The total RNA was extracted from HUVECs with an
Easy-spin™ Total RNA Extraction Kit (iNtRON Bio-
technology, Seoul, Republic of Korea). Complementary
DNAs (cDNAs) were synthesized using the iScript™
cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA),
according to the manufacturer’s instructions. qPCR,
which was performed with SsoAdvanced™ Universal
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Time Detection System (Bio-Rad), was initiated by
activation at 95°C for 30 s, followed by 40 cycles of
amplification (denaturation at 95°C for 5 s, annealing/
elongation at 60°C for 30 s). Gene expression was nor-
malized to the housekeeping gene for glyceraldehyde-
3-phosphate dehydrogenase (GAPDH). Each sample
was measured in triplicates. The sequences of gene
specific primers and their amplicons are illustrated in
Table 2.
Western blot analysis
Western blot analysis was performed as previously de-
scribed [11]. The total focal adhesion kinase (FAK) and
phospho-FAK (pFAK, Y397) antibodies were obtained
from Cell Signaling Technology (Danvers, MA, USA), and
the β-actin antibody was obtained from Bio-Rad.
Statistics
Statistical data analysis was performed using one-way
analysis of variance and the level of statistical signifi-
cance was set at p < 0.05.
Results
SMYGT inhibits angiogenesis in vitro and in ovo
The anti-angiogenic potential of SMYGT was evaluated
with an in vitro tube formation assay mediated
by HUVECs. In the absence of SMYGT, HUVECs
constructed blood vessel-like tubes by connecting
with neighboring cells (Additional file 1A, 0 μg/mL of
SMYGT). However, the SMYGT treatment interrupted
this intercellular connection by inhibiting tube forma-
tion (Additional file 1A, 100–400 μg/mL of SMYGT).
Image analysis revealed that the degree of HUVEC-
mediated angiogenesis, based on tube length and
branch numbers, was decreased by SMYGT in a dose-
dependent manner (Figure 1A). The inhibitory effect
of 200 μg/mL of SMYGT was comparable to that of
5 μM of sulforaphane, a positive control drug, and
tube formation was completely inhibited by 400 μg/mL
of SMYGT.
Next, we confirmed the anti-angiogenic potential of
SMYGT in ovo. Fertilized eggs were treated with
SMYGT (0-400 μg/egg) on ED4.5, and the degree of ves-
sel formation on CAMs was scored 2 days later. Blood
vessel formation was impeded, and the avascular zone
was increased by SMYGT in a dose-dependent manner
(Figure 1B). Retinoic acid (RA, 1μg/egg) was used as aTable 2 Sequences of gene specific primers
Target Forward (5′→ 3′)
MMP2 ATGCCGCCTTTAACTGGAG
GAPDH AAGGCTGAGAACGGGAAGpositive control. The proportion of eggs exhibiting anti-
angiogenic effects is summarized in Table 3. Dead embryo
was not observed in the tested dose ranges of SMYGT, in-
dicating that SMYGT-mediated anti-angiogenesis in ovo
was not due to SMYGT toxicity.
SMYGT potently inhibits cell adhesion and the
invasiveness of HUVECs
To understand the anti-angiogenic activity of SMYGT,
the cellular responses of HUVECs to SMYGT treatment
were investigated in vitro. First, we determined the
cytotoxicity of SMYGT in HUVECs based on cellular
membrane integrity. When HUVECs were exposed to
increasing concentrations of SMYGT, no significant
morphological changes was observed (Additional file
1B), and HUVECs maintained normal cell growth and a
viability of > 90% in concentrations up to 400 μg/mL of
SMYGT (Figure 2A). These data suggest that the anti-
angiogenic potential of SMYGT, as demonstrated by
HUVEC-mediated tube formation and in ovo CAM as-
says, was not due to its cytotoxicity. An in vitro wound
healing assay used to determine cell mobility demon-
strated that although a slight inhibitory effect was ob-
served at SMYGT concentrations ≥200 μg/mL, but
HUVECs showed normal cell movement when com-
pared to cells treated with 5 μM of sulforaphane, a posi-
tive control drug (Additional file 1C). Image analysis did
not reveal that SMYGT induced any significant changes
in cell movement (Figure 2B). In contrast, SMYGT re-
duced endothelial cell adhesion to the extracellular
matrix (Additional file 1D), and image analysis revealed
that 400 μg/mL of SMYGT reduced cell adhesion by
80.6% (Figure 2C). Furthermore, SMYGT reduced cellu-
lar invasiveness through the membrane (Additional file
1E), and the inhibitory effect of 200 μg/mL of SMYGT
was comparable to that of 5 μM of sulforaphane
(Figure 2D).
SMYGT down-regulates angiogenesis-related FAK
signaling and MMP2 expression
As shown in Figure 2C, SMYGT potently inhibited
the adhesion of HUVECs to matrix supports. Because
integrin-FAK signaling plays a key role in cell adhesion,
and activation of integrin leads to phosphorylation of
FAK [12], we determined the level of phosphorylated
FAK following SMYGT treatment in HUVECs. SMYGT
reduced the phosphorylation of FAK compared to ve-
hicle treatment (Figure 3A). The total FAK and β-actin,Reverse (5′→ 3′) Amplicon (bp)
GGGAAGCCAGGATCCATTTT 103
GGACTCCACGACGTACTC 114
Figure 1 Anti-angiogenic potential of SMYGT in vitro and in ovo. (A) HUVECs cultured on BME-pre-coated supports were exposed to
different concentrations of SMYGT for 12 h. The tube length and branch numbers were determined by analyzing digitally captured images.
Sulforaphane (Sulfo, 5 μM) was administered in parallel as a positive control drug. Relative tube formation was determined by comparing
each group with the vehicle treated group (0 μg/mL SMYGT), and the data are presented as the means ± standard deviation (S.D.) of
triplicate experiments. *P < 0.05, **P < 0.01, ***P < 0.001. (B) At ED4.5, A quarter size of thermanox coverslips containing variable amounts
of SMYGT (0, 200, 400 μg/disc) were applied to the CAMs. After 2 days of incubation, 10% skimmed milk solution was injected into the
CAM for observation of the inhibition zone of angiogenesis and digital images were captured. Retinoic acid (RA, 1 μg/disc) used as a
control for inhibition of new vessel formation.
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Table 3 Summary of anti-angiogenic effect of SMYGT in
chick CAM assays
Drugs Dose (μg per egg) Tested eggs (n) Eggs showing anti-
angiogenesis (n (%))*
Vehicle - 10 1 (10.0)
RA 1 10 9 (90.0)
SMYGT 200 10 3 (25.0)
400 10 8 (66.6)
*CAM showing an avascular zone similar to RA-treated CAM was scored as positive.
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changed by SMYGT treatment. Therefore, SMYGT may
affect cell adhesion by down-regulating integrin-FAK
signaling pathway.
Invasive cell migration is an important function of
both endothelial and cancer cells during angiogenesis.
Cellular invasiveness depends on the enzymatic degrad-
ation of the extracellular matrix, which is mediated by
MMPs. We determined the effect of SMYGT on MMP2
and 9 enzyme activities and intracellular mRNA by gela-
tinase activity gels and qPCR, respectively. The activity
gel assay demonstrated that SMYGT inhibited MMP2




Figure 2 Effects of SMYGT on the HUVEC-mediated angiogenic proce
of SMYGT for 24 h and measured using an automatic cell counter to deter
lawn of HUVECs, and then cells were cultured in the presence or absence
analyzing digital images. (C) HUVECs were resuspended in culture medium
culture plates that were pre-coated with Matrigel. After 2 h, the adherent c
Serum-starved HUVECs were inoculated into the cell culture inserts pre-coa
SMYGT. After 16 h, chemotactic HUVECs that invaded through the Matrigel
(Sulfo) was included in these assays for a positive control drug. All data, ex
experiments compared to the vehicle treatment group. *P < 0.05, **P < 0.0right) dependent manner. MMP9 enzyme activity was
too low to be detected in the activity gel assay. The de-
crease in MMP2 enzyme activity triggered by SMYGT
was observed in parallel with a decrease in intracellular
MMP2 mRNA, as determined by qPCR (Figure 3B,
lower panel); therefore, SMYGT may inhibit HUVEC in-
vasiveness by down-regulating MMP2 activity at the
transcription level.
Discussion
Angiogenesis is a multi-stepped process of de novo ves-
sel formation from the established blood vasculature by
endothelial cells. It is essential for continuous tumor
growth because it supplies tumors with nutrients and
oxygen and removes cellular waste, which may be toxic
to cancer cells, from the tumor mass. Since the idea of
tumor angiogenesis was suggested in the 1970s by Folk-
man [13], the blockade of tumor-induced angiogenesis
has been considered to be an attractive anticancer
strategy because anti-angiogenic agents can be used irre-
spective of cancer types because tumor-induced angio-
genesis is a general hallmark of cancer, and the agents




ss in vitro. (A) HUVECs were cultured in the presence and absence
mine cell growth and viability. (B) Scratches were applied to the
of SMYGT. After 12 h, the relative cell motility was determined by
containing various concentrations of SMYGT and then inoculated in
ells were fixed, stained, and then counted under a microscope. (D)
ted with Matrigel and then cultured in the presence or absence of
were stained and counted under a microscope. Sulforaphane
cept viability, are presented as the relative means ± S.D. of triplicate
1, ***P < 0.001.
Figure 3 The effects of SMYGT on FAK signaling and MMP2 expression in HUVECs. (A) Time-(left, 200 μg/mL of SMYGT) and dose-(right, 24
h) dependent effect of SMYGT on phosphorylation of the intracellular FAK protein were determined using western blot analyses. β-actin was
used to confirm equal loading of total proteins. (B) Time-(left, 200 μg/mL of SMYGT) and dose-(right, 24 h) dependent changes of MMP2 enzyme
activities and mRNA induced by SMYGT were determined by zymography (top) and qPCR (bottom), respectively. A PAGE gel stained with
Coomassie blue solution (middle) is presented to demonstrate equal loading of the proteins for the MMP2 zymography. V, vehicle; S, SMYGT.
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esis is a process that is coordinated by the functional
balance between pro-angiogenic and anti-angiogenic fac-
tors. Therefore, anti-angiogenesis can be accomplished
by blocking the signaling pathway mediated by pro-
angiogenic proteins, such as vascular endothelial growth
factor (VEGF) and basic fibroblast growth factor, and/or
by up-regulating the expression of endogenous anti-
angiogenic proteins, such as endostatin and tissue in-
hibitor of metalloproteinases-1 (TIMP-1).In this study, we described the novel anti-angiogenic
effect of SMYGT, an extract that is a traditional Korean
medicinal cocktail. We demonstrated that SMYGT ex-
erts its anti-angiogenic potential in vitro by inhibiting
the cell adhesion and invasiveness of endothelial cells.
We also demonstrated that SMYGT inhibits intracellular
FAK signaling by modulating its phosphorylation status
and down-regulates MMP2 activity by reducing intracel-
lular levels of MMP2 mRNA. In general, phosphoryl-
ation of FAK is known to be related to the adhesion of
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and survival of endothelial cells [16]. We observed that
SMYGT down-regulated FAK signaling and inhibited
endothelial cell adhesion to the extracellular matrix, but
cell proliferation, viability, and mobility were not af-
fected by SMYGT. This differential response of HUVECs
to SMYGT may be related to the partial inhibition of
FAK by SMYGT, which is adequate to affect cell adhe-
sion but not sufficient to affect cell survival, prolifera-
tion, and motility. FAK signaling is considered to be a
promising anti-cancer target because phosphorylation of
FAK, particularly at Y397, is also critical for angiogen-
esis, metastasis, and the invasion of tumor cells because
of its effects on regulating cell adhesion to the extracel-
lular matrix, cell survival, motility, and proliferation
[17,18]. MMPs also contribute to endothelial cell-
mediated angiogenesis by loosening focal cell-to-cell
interaction and by degrading the basement membrane
and extracellular matrix surrounding blood vessels
[19,20]. In this study, we demonstrated that SMYGT
could down-regulate MMP2 activity in HUVECs. How-
ever, MMP9 was not detected in a gelatinase activity gel
assay using HUVEC cultured medium which is consist-
ent with our previous studies of other anti-angiogenic
medicinal herb extracts [11]. MMP2 activity has also
been reported to be effectively reduced by anti-cancer
agents that target tumor vessel formation [21,22].
MMP2 activity can be regulated during the transcriptional,
post-transcriptional (e.g., mRNA stability), translational,
and post-translation (e.g., extracellular secretion) steps. In
this study, we suggest that SMYGT can down-regulate
MMP2 activity by decreasing intracellular level of
mRNA. However, we did not investigate whether
SMYGT-mediated MMP2 regulation is controlled tran-
scriptionally or post-transcriptionally. It is known that
when endothelial cells are subjected to hypoxic condi-
tions (low PO2) such as inside of a tumor mass, MMP2
expression is elevated, and its specific endogenous in-
hibitor TIMP-2 and the hypoxic conditions enhance
MMP2-dependent endothelial cell migration [19].
SMYGT, a traditional medicinal decoction, has been
used to treat cancer patients in Korean Oriental medi-
cine clinics [9], and it has been revealed that this herbal
prescription has an inhibitory effect on inflammation
and fecal enzyme activity in an ulcerative colitis animal
model [10]. Modified SMYGT has also demonstrated
potentially cytotoxic activity against various cancer cells,
such as A549, SK-OV-3, B165-F10, and SK-MEL-2, and
it has been shown to suppress lung metastasis and
angiogenesis in an animal model [9]. SMYGT consists of
four components in equal weights. Sargassum fusiforme
and Laminaria japonica are members of the brown algae
family, which is widely distributed in Far East Asia,
including Korea, China, and japan; S. fusiforme and L.japonica have been used as therapeutic agents for thou-
sands of years [23,24], and polysaccharides extracted
from S. fusiforme and L. japonica are known to have
various biological activities, such as anti-tumor [25],
anti-oxidant [24], immunity enhancing [26], and anti-
hyperlipidemia activities [27]. The shell of Ostrea gigas
has been prescribed with other medicinal herbs to treat
various symptoms, such as palpitations, insomnia, dizzi-
ness, tinnitus, scrofula, subcutaneous nodules, and ab-
dominal masses [28]. Recent studies have revealed that
Ostreae Concha pharmacologically functions to boost
the immune system and relieves gastric ulcers, sedation,
viral infections, and tumors [29]. Prunella vulgaris is
widely distributed in the temperate zone, and it has been
used to treat inflammation, eye pain, headaches, and
dizziness [30]. P. vulgaris has anti-inflammatory, anti-
bacterial, anti-viral, and anti-tumor effects, and these
pharmacological functions may be attributed to its im-
munomodulatory activity [31]. In the prescription,
Sargassum and Laminariae Thallus primarily help to
soften and resolve hard masses, Prunellae Spica re-
duces pathogenic heat, and Ostreae Concha alleviates
pains. These ingredients enhance the efficacy of SMYGT,
according to traditional oriental medicine theory. We did
not determine whether the anti-angiogenic potential of
SMYGT is attributed to a single component or a combin-
ation of components of SMYGY.
Conclusion
In summary, in the present study, we demonstrated the
novel anti-angiogenic activity of SMYGT, which has
been traditionally used to treat diverse diseases, includ-
ing cancer. SMYGT exerts its anti-angiogenic potential
by down-regulating the pro-angiogenic protein MMP2
and by inhibiting the cell adhesion-related FAK signaling
pathway. Further rigorous studies should be performed to
determine the detailed anti-angiogenic mechanism of
SMYGT and to identify its active constituents to develop
anti-cancer drugs using SMYGT or its active constituents.
Additional file
Additional file 1: Determination of anti-angiogenic potential of
SMYGT in vitro. To investigate anti-angiogenic potential of SMYGT,
HUVEC was exposed to SMYGT (0-400 μg/mL). PBS and sulforaphane
(Sulfo, 5 μM) were treated as a vehicle and a positive control, respectively.
Cells were observed under the inverted microscope at indicated
magnifications. (A) tube formation (× 40), (B) cell growth (× 200),
(C) cell mobility (× 100), (D) cell adhesion (× 100), and (E) cell invasion
(× 100). At least three independent experiments were performed and
representative images of each assay are shown.
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